CY2020023I2 - Αναστολεiς βητα-λακταμασων - Google Patents

Αναστολεiς βητα-λακταμασων

Info

Publication number
CY2020023I2
CY2020023I2 CY2020023C CY2020023C CY2020023I2 CY 2020023 I2 CY2020023 I2 CY 2020023I2 CY 2020023 C CY2020023 C CY 2020023C CY 2020023 C CY2020023 C CY 2020023C CY 2020023 I2 CY2020023 I2 CY 2020023I2
Authority
CY
Cyprus
Prior art keywords
lactamas
inhibitors
beta
lactamas inhibitors
Prior art date
Application number
CY2020023C
Other languages
English (en)
Other versions
CY2020023I1 (el
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY2020023I2 publication Critical patent/CY2020023I2/el
Publication of CY2020023I1 publication Critical patent/CY2020023I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
CY2020023C 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων CY2020023I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
EP09701487.2A EP2231667B1 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
CY2020023I2 true CY2020023I2 (el) 2020-11-25
CY2020023I1 CY2020023I1 (el) 2020-11-25

Family

ID=40642204

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20131101079T CY1114900T1 (el) 2008-01-18 2013-12-03 Αναστολεις βητα-λακταμασων
CY20151100288T CY1116243T1 (el) 2008-01-18 2015-03-23 Αναστολεiς βητα-λακταμασων
CY2020024C CY2020024I2 (el) 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων
CY2020025C CY2020025I2 (el) 2008-01-18 2020-07-15 Αναστολεις βητα-λακταμασων
CY2020023C CY2020023I1 (el) 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CY20131101079T CY1114900T1 (el) 2008-01-18 2013-12-03 Αναστολεις βητα-λακταμασων
CY20151100288T CY1116243T1 (el) 2008-01-18 2015-03-23 Αναστολεiς βητα-λακταμασων
CY2020024C CY2020024I2 (el) 2008-01-18 2020-07-15 Αναστολεiς βητα-λακταμασων
CY2020025C CY2020025I2 (el) 2008-01-18 2020-07-15 Αναστολεις βητα-λακταμασων

Country Status (39)

Country Link
US (2) US8487093B2 (el)
EP (2) EP2666774B1 (el)
JP (3) JP5038509B2 (el)
KR (2) KR101800610B1 (el)
CN (2) CN102827067B (el)
AU (1) AU2009206119C1 (el)
BR (1) BRPI0906871B1 (el)
CA (1) CA2712783C (el)
CO (1) CO6331438A2 (el)
CR (1) CR11626A (el)
CY (5) CY1114900T1 (el)
DK (2) DK2666774T3 (el)
DO (1) DOP2010000218A (el)
EC (2) ECSP10010345A (el)
ES (2) ES2533826T3 (el)
FR (3) FR20C1030I2 (el)
HK (2) HK1143809A1 (el)
HN (1) HN2010001395A (el)
HR (2) HRP20131123T1 (el)
HU (2) HUS2000023I1 (el)
IL (1) IL206395A (el)
LT (3) LTC2666774I2 (el)
LU (1) LUC00165I2 (el)
MA (1) MA32025B1 (el)
ME (1) ME02089B (el)
MX (1) MX2010007823A (el)
MY (1) MY162532A (el)
NI (1) NI201000115A (el)
NL (2) NL301051I2 (el)
NO (1) NO2020024I1 (el)
NZ (1) NZ586861A (el)
PL (2) PL2231667T3 (el)
PT (2) PT2231667E (el)
RS (2) RS53862B1 (el)
RU (1) RU2445314C9 (el)
SI (2) SI2231667T1 (el)
UA (1) UA101966C2 (el)
WO (1) WO2009091856A2 (el)
ZA (1) ZA201005333B (el)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
CN104892490B (zh) * 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
MX361020B (es) * 2011-06-17 2018-11-26 Pfizer Anti Infectives Ab Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
RU2578370C2 (ru) * 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
PT2872510T (pt) * 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AU2013207510A1 (en) * 2012-01-06 2014-07-31 The Regents Of The University Of California Compositions, methods of use, and methods of treatment
CN104334555A (zh) 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 异噁唑β-内酰胺酶抑制剂
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343645A (zh) * 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
SG11201407295YA (en) 2012-05-08 2014-12-30 Codexis Inc Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX366948B (es) * 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
EP2915805A4 (en) * 2012-11-01 2016-03-23 Kaneka Corp METHOD FOR PRODUCING AN OPTICALLY ACTIVE BICYCLIC UREA COMPOUND
US9422314B2 (en) 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
EA201591003A1 (ru) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
NZ711328A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
NZ711326A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
US9556174B2 (en) 2013-03-08 2017-01-31 Wockhardt Limited (2S, 5R)-sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
NZ711327A (en) 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
MX362348B (es) * 2013-06-10 2019-01-11 Merck Sharp & Dohme Preparacion de 4-((1r,2s,5r)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[ 3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de ter-butilo.
ES2793201T3 (es) 2013-09-24 2020-11-13 Meiji Seika Pharma Co Ltd Procedimiento de producción de derivados y productos intermedios de diazabiciclooctano
WO2015051101A1 (en) * 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
AR097971A1 (es) * 2013-10-08 2016-04-20 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
US9604986B2 (en) 2013-11-26 2017-03-28 Wockhardt Limited Polymorphs and process for preparation of (2S, 5R)-7-oxo-N-[(2S)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
IN2014MU01195A (el) * 2014-03-29 2015-10-02 Wockhardt Ltd
WO2015150890A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN106687465B (zh) 2014-06-11 2019-04-16 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112017010132B1 (pt) * 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10053460B2 (en) 2014-12-02 2018-08-21 Merck Sharp & Dohme Corp. Process for the preparation of tert-butyl 4-((2S ,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
CN107001366B (zh) 2014-12-05 2020-08-28 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶以及稳定的冻干制剂的制备方法
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3277685B1 (en) 2015-03-31 2021-01-13 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US10183943B2 (en) * 2015-05-07 2019-01-22 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017045510A1 (zh) * 2015-09-16 2017-03-23 山东轩竹医药科技有限公司 β-内酰胺酶抑制剂及其用途
KR20180051559A (ko) 2015-10-02 2018-05-16 주식회사 레고켐 바이오사이언스 베타-락타마제의 억제용 조성물 및 억제 방법
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10501464B2 (en) * 2015-12-11 2019-12-10 Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
WO2017167218A1 (zh) * 2016-03-31 2017-10-05 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
SG11201809575TA (en) 2016-06-09 2018-11-29 Codexis Inc Biocatalysts and methods for hydroxylation of chemical compounds
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
MX2019003060A (es) * 2016-09-16 2019-07-08 Entasis Therapeutics Ltd Compuestos inhibidores de beta-lactamasa.
EP3515915B1 (en) * 2016-09-19 2021-08-04 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
EP3592362A4 (en) 2017-03-06 2020-09-02 Venatorx Pharmaceuticals, Inc. SOLID FORMS AND COMBINATION COMPOSITIONS WITH A BETA LACTAMASE INHIBITOR AND USES THEREOF
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
IL270380B (en) 2017-05-08 2022-06-01 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN115745910A (zh) 2017-07-21 2023-03-07 安塔比奥公司 化学化合物
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
EP3719020B1 (en) 2017-12-01 2022-09-21 Qilu Pharmaceutical Co., Ltd. Crystal form of beta-lactamase inhibitor and preparation method therefor
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CA3089150A1 (en) 2018-01-25 2019-01-24 Suzhou Sinovent Pharmaceuticals Co., Ltd. .beta.-lactamase inhibitor and use thereof
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CA3110111A1 (en) * 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11897844B2 (en) * 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
CA3114618C (en) * 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
CA3133071A1 (en) 2019-03-12 2020-09-17 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
CN114206851A (zh) * 2019-04-26 2022-03-18 默沙东公司 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US11814385B2 (en) * 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023220324A1 (en) * 2022-05-11 2023-11-16 The Regents Of The University Of Colorado A Body Corporate Antibiotic composition and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
ES2090393T3 (es) 1991-04-11 1996-10-16 Hoffmann La Roche Beta-lactamas.
US5854239A (en) 1993-12-29 1998-12-29 Pfizer Inc. Diazabicyclic neuokinin antagonists
JP3199300B2 (ja) * 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
DE69623497T2 (de) 1995-12-21 2003-05-28 Sankyo Co 1-methylcarbapenem-derivate
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) * 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
DE60024455T2 (de) 1999-07-06 2006-08-03 Methylgene, Inc., Saint-Laurent Sulfonamidomethylphosphonat-BETA-LACTAMASE-Inhibitoren
NZ517239A (en) * 1999-08-10 2004-09-24 British Biotech Pharm Antibacterial agents
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
DE60123827T2 (de) 2000-11-16 2007-05-31 Sankyo Co., Ltd. 1-methylcarbapenemderivate
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) * 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
CN1845897A (zh) 2003-07-09 2006-10-11 帕拉特克药品公司 取代的四环素化合物
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
CA2540646A1 (en) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibacterial amide macrocycles
WO2005082012A2 (en) 2004-02-24 2005-09-09 Ssci, Inc. Analysis and screening of solid forms using the atomic pair distribution function
DK2484680T3 (da) * 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa

Also Published As

Publication number Publication date
CR11626A (es) 2010-09-13
WO2009091856A2 (en) 2009-07-23
FR20C1031I2 (fr) 2022-07-29
CA2712783A1 (en) 2009-07-23
ECSP10010345A (es) 2010-08-31
CY2020025I1 (el) 2020-11-25
JP5597164B2 (ja) 2014-10-01
CY2020025I2 (el) 2020-11-25
BRPI0906871A2 (pt) 2020-07-28
JP2011510012A (ja) 2011-03-31
AU2009206119A1 (en) 2009-07-23
LTPA2020518I1 (lt) 2020-07-27
NL301051I2 (nl) 2020-09-03
MA32025B1 (fr) 2011-01-03
LTC2666774I2 (lt) 2022-01-25
FR20C1031I1 (el) 2020-02-10
IL206395A0 (en) 2010-12-30
US8487093B2 (en) 2013-07-16
NI201000115A (es) 2011-07-08
JP2011207900A (ja) 2011-10-20
AU2009206119C1 (en) 2016-05-26
RU2445314C9 (ru) 2013-04-10
CY2020024I1 (el) 2020-11-25
NL301050I2 (nl) 2020-09-03
KR101648728B1 (ko) 2016-08-17
CY1114900T1 (el) 2016-12-14
ZA201005333B (en) 2011-04-28
FR20C1030I1 (fr) 2020-02-10
PL2666774T3 (pl) 2015-06-30
CN102827067A (zh) 2012-12-19
RS53862B1 (en) 2015-08-31
JP2012214475A (ja) 2012-11-08
KR20160099117A (ko) 2016-08-19
BRPI0906871B1 (pt) 2021-09-28
HUS000504I2 (hu) 2021-03-29
UA101966C2 (en) 2013-05-27
AU2009206119B2 (en) 2012-06-07
US20110294777A1 (en) 2011-12-01
CY1116243T1 (el) 2017-03-15
JP5038509B2 (ja) 2012-10-03
IL206395A (en) 2015-04-30
LUC00165I2 (el) 2021-08-16
CO6331438A2 (es) 2011-10-20
FR20C1032I1 (el) 2020-02-10
PT2666774E (pt) 2015-04-13
ECSP10010568A (es) 2010-11-30
CY2020023I1 (el) 2020-11-25
LTC2231667I2 (lt) 2021-07-26
MX2010007823A (es) 2010-08-10
SI2231667T1 (sl) 2013-12-31
LTPA2020516I1 (lt) 2020-07-27
EP2666774B1 (en) 2015-01-07
RU2445314C1 (ru) 2012-03-20
HUS000513I2 (hu) 2021-03-29
RS53052B (en) 2014-04-30
CN101918407A (zh) 2010-12-15
EP2231667A2 (en) 2010-09-29
ES2433744T3 (es) 2013-12-12
HK1143809A1 (en) 2011-01-14
CN101918407B (zh) 2014-02-26
KR20100130176A (ko) 2010-12-10
HUS2000024I1 (hu) 2021-03-29
CA2712783C (en) 2013-03-19
HRP20150269T1 (hr) 2015-04-24
DK2666774T3 (en) 2015-03-23
HUS2000023I1 (hu) 2021-03-29
NZ586861A (en) 2011-12-22
DOP2010000218A (es) 2010-08-31
HN2010001395A (es) 2012-11-12
LTPA2020517I1 (lt) 2020-07-27
ES2533826T3 (es) 2015-04-15
HK1186180A1 (en) 2014-03-07
EP2231667B1 (en) 2013-09-04
MY162532A (en) 2017-06-15
CY2020024I2 (el) 2020-11-25
JP5422020B2 (ja) 2014-02-19
CN102827067B (zh) 2015-09-23
FR20C1030I2 (fr) 2021-08-27
ME02089B (me) 2014-04-30
EP2666774A1 (en) 2013-11-27
DK2231667T3 (da) 2013-12-16
WO2009091856A3 (en) 2009-12-03
PL2231667T3 (pl) 2014-01-31
PT2231667E (pt) 2013-12-13
US20130274475A1 (en) 2013-10-17
KR101800610B1 (ko) 2017-11-23
HRP20131123T1 (hr) 2013-12-20
NO2020024I1 (no) 2020-08-10
SI2666774T1 (sl) 2015-04-30
FR20C1032I2 (fr) 2022-07-29

Similar Documents

Publication Publication Date Title
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0907376A2 (pt) Fotobiorretador
DE602009000234D1 (de) msignals
BRPI0918564A2 (pt) inibidores
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
DK2240506T3 (da) IAP inhibitorer
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909637A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
AT507449A3 (de) Dämmstoffbefestiger
DK2344933T3 (da) Uretui
DK2331548T3 (da) Proteasehæmmere
DE502008003019D1 (de) Einschraubverschraubung
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
DE502008002554D1 (de) Falztaschenvorrichtung
FI20086047A0 (fi) Kaksikanavavastaanotto